Reassessing biomarker signatures in RA‐ILD and the impact of gender, environment, and disease activity: comment on the article by Wheeler et al

Documenti analoghi

• Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to JAK inhibitors versus adalimumab: a nationwide cohort study: comment on the article by Hoisnard et al
  di: Jing‐jin Hu, et al.
  Pubblicazione: (2025)
• Interstitial lung disease in ANCA‐associated vasculitis: comment on the article by Chalkia et al
  di: Claudia Iannone, et al.
  Pubblicazione: (2026)
• Unexplored limitations in a randomized trial that examines efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: comment on the article by Merrill et al
  di: Qianyu Guo, et al.
  Pubblicazione: (2025)
• Drivers of subclinical vascular disease in systemic lupus erythematosus: comment on the article by Oliveira et al
  di: Biao Song, et al.
  Pubblicazione: (2025)
• Epitope spreading and systemic sclerosis: comment on the article by Kotani et al
  di: Ranjeet Singh Mahla
  Pubblicazione: (2025)